Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
NCT ID: NCT05609812
Last Updated: 2025-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE3
INTERVENTIONAL
2022-11-02
2028-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis
NCT00573157
Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil
NCT01369628
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
NCT01972568
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
NCT00624338
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atacicept Dose
Atacicept Dose once weekly subcutaneous (SC) Injection
Atacicept
Once weekly subcutaneous (SC) injections by prefilled syringe
Placebo to match Atacicept
Placebo to match Atacicept once weekly subcutaneous (SC) injection
Placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atacicept
Once weekly subcutaneous (SC) injections by prefilled syringe
Placebo
placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Must have the ability to understand and sign and date a written informed consent form
3. Diagnosis of SLE
4. Biopsy- Proven Active LN
5. Requires high-dose corticosteroids and immunosuppressive therapy for the treatment of active LN
6. Subject is willing to take oral MMF for the duration of the study
Exclusion Criteria
2. Sclerosis in 50% of glomeruli on renal biopsy.
3. Evidence of rapidly progressive glomerulonephritis.
4. Currently requiring renal dialysis or expected to require dialysis during the study.
5. Serum igG \<7 g/L
6. Active infection or high infectious risk
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vera Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joanne Curley
Role: STUDY_DIRECTOR
Chief Development Officer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vera Site # 0139
Huntsville, Alabama, United States
Vera Site # 0138
La Jolla, California, United States
Vera Site # 0127
La Palma, California, United States
Vera Site # 0129
Long Beach, California, United States
Vera Site # 0135
Northridge, California, United States
Vera Site # 0136
Northridge, California, United States
Vera Site # 0130
Santa Clarita, California, United States
Vera Site # 0131
Torrance, California, United States
Vera Site # 0143
New Haven, Connecticut, United States
Vera Site # 0140
Gainesville, Florida, United States
Vera Site # 0128
Miami, Florida, United States
Vera Site # 0134
Atlanta, Georgia, United States
Vera Site # 0137
Augusta, Georgia, United States
Vera Site # 0144
Augusta, Georgia, United States
Vera Site # 0147
Lawrenceville, Georgia, United States
Vera Site # 0109
Chicago, Illinois, United States
Vera Site # 0133
Las Vegas, Nevada, United States
Vera Site # 0149
Summit, New Jersey, United States
Vera Site # 0146
New York, New York, United States
Vera Site # 0142
New York, New York, United States
Vera Site # 0148
Cleveland, Ohio, United States
Vera Site # 0145
Columbus, Ohio, United States
Vera SIte # 0132
Jackson, Tennessee, United States
Vera Site # 0125
Dallas, Texas, United States
Vera Site # 0126
Dallas, Texas, United States
Vera Site # 0122
El Paso, Texas, United States
Vera Site # 0141
Coto Laurel, , Puerto Rico
Vera Site # 0349
A Coruña, , Spain
Vera Site # 0348
Barcelona, , Spain
Vera Site # 0347
Barcelona, , Spain
Vera Site #0351
Santander, , Spain
Vera Site # 0350
Seville, , Spain
Vera Site # 0346
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Vera Therapeutics, Inc. Company Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VT-001-0070
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.